Toronto Dominion Bank increased its position in Allergan plc (NYSE:AGN) by 13.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 143,364 shares of the company’s stock after buying an additional 16,487 shares during the quarter. Toronto Dominion Bank’s holdings in Allergan were worth $23,452,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Edgewood Management LLC increased its holdings in Allergan by 24.3% in the 3rd quarter. Edgewood Management LLC now owns 4,445,924 shares of the company’s stock valued at $911,192,000 after purchasing an additional 869,248 shares in the last quarter. Baupost Group LLC MA boosted its position in Allergan by 21.9% in the third quarter. Baupost Group LLC MA now owns 2,964,203 shares of the company’s stock valued at $607,513,000 after buying an additional 531,600 shares in the last quarter. Parnassus Investments CA boosted its position in Allergan by 20.4% in the fourth quarter. Parnassus Investments CA now owns 2,161,833 shares of the company’s stock valued at $353,633,000 after buying an additional 365,914 shares in the last quarter. Epoch Investment Partners Inc. boosted its position in Allergan by 1.0% in the third quarter. Epoch Investment Partners Inc. now owns 1,805,608 shares of the company’s stock valued at $370,060,000 after buying an additional 17,068 shares in the last quarter. Finally, Legal & General Group Plc boosted its position in Allergan by 5.3% in the third quarter. Legal & General Group Plc now owns 1,739,410 shares of the company’s stock valued at $356,484,000 after buying an additional 87,953 shares in the last quarter. 79.76% of the stock is currently owned by institutional investors and hedge funds.

In other Allergan news, Chairman Brent L. Saunders acquired 4,600 shares of the business’s stock in a transaction that occurred on Wednesday, December 6th. The shares were acquired at an average cost of $164.74 per share, for a total transaction of $757,804.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Christopher J. Coughlin acquired 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 5th. The stock was acquired at an average price of $163.30 per share, for a total transaction of $1,633,000.00. The disclosure for this purchase can be found here. Insiders purchased 17,630 shares of company stock worth $2,890,057 over the last 90 days. 0.36% of the stock is currently owned by company insiders.

A number of equities analysts have commented on the stock. Bank of America boosted their price target on shares of Allergan from $208.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday, February 7th. Credit Suisse Group boosted their price target on shares of Allergan from $214.00 to $215.00 and gave the company an “outperform” rating in a research report on Wednesday, February 7th. Leerink Swann boosted their price target on shares of Allergan from $237.00 to $242.00 and gave the company an “outperform” rating in a research report on Wednesday, February 7th. ValuEngine lowered shares of Allergan from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, Cantor Fitzgerald restated a “hold” rating and issued a $191.00 price target on shares of Allergan in a research report on Tuesday, February 6th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and fourteen have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $227.23.

Allergan plc (NYSE:AGN) opened at $156.90 on Wednesday. Allergan plc has a 12-month low of $156.11 and a 12-month high of $256.80. The stock has a market cap of $52,790.00, a P/E ratio of -13.12, a PEG ratio of 1.16 and a beta of 1.19. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.88 and a current ratio of 2.04.

Allergan (NYSE:AGN) last announced its earnings results on Tuesday, February 6th. The company reported $4.86 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $4.74 by $0.12. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.28%. The company had revenue of $4.33 billion for the quarter, compared to analyst estimates of $4.28 billion. During the same period in the prior year, the business earned $3.90 earnings per share. Allergan’s quarterly revenue was up 12.0% on a year-over-year basis. research analysts anticipate that Allergan plc will post 15.56 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 28th. Investors of record on Wednesday, February 28th will be issued a $0.72 dividend. This is a positive change from Allergan’s previous quarterly dividend of $0.70. This represents a $2.88 annualized dividend and a yield of 1.84%. The ex-dividend date is Tuesday, February 27th. Allergan’s dividend payout ratio is currently -23.35%.

COPYRIGHT VIOLATION WARNING: “Toronto Dominion Bank Raises Position in Allergan plc (AGN)” was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://theolympiareport.com/2018/02/14/toronto-dominion-bank-raises-position-in-allergan-plc-agn.html.

About Allergan

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.